SSL5 and Platelet Activation: Understanding the Interaction
Author Information
Author(s): Hu Houyuan, Armstrong Paul C. J., Khalil Elie, Chen Yung-Chih, Straub Andreas, Li Min, Soosairajah Juliana, Hagemeyer Christoph E., Bassler Nicole, Huang Dexing, Ahrens Ingo, Krippner Guy, Gardiner Elizabeth, Peter Karlheinz
Primary Institution: Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia
Hypothesis
This study investigates the interaction between Staphylococcal superantigen-like protein 5 (SSL5) and platelet glycoproteins to identify potential glycans for therapeutic targeting.
Conclusion
The study identifies GPVI as a novel receptor for SSL5 on platelets and demonstrates the efficacy of glycan-based inhibitors to prevent SSL5-induced platelet activation.
Supporting Evidence
- SSL5 was shown to bind to human platelets in a concentration-dependent manner.
- SSL5 induced increased levels of P-selectin and active GPIIb/IIIa on platelets.
- Specific glycan families were identified as important in mediating SSL5-platelet interactions.
- Glycan-based inhibitors were effective in reducing SSL5-induced platelet activation.
Takeaway
The researchers found that a protein from bacteria can make platelets in our blood activate, and they discovered some sugars that might help stop this from happening.
Methodology
The study used flow cytometry, immunoprecipitation, surface plasmon resonance, and a glycan binding array to analyze SSL5 interactions with platelets.
Limitations
Further work is required to prove SSL5-platelet effects in vivo.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website